Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 07/10/26
5 Words A Dividend Investor Never Wants To Hear, And Three Signs You Are About To Hear Them.24/7 Wall Street • 07/10/26
Fundstrat's Tom Lee: AI Is a Once in a Lifetime Story – Why Easing Inflation in H2 2026 Could Fuel the Next Rally24/7 Wall Street • 07/09/26
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 07/08/26
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF PlatformBusiness Wire • 07/08/26
Johnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallBenzinga • 07/06/26
Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?The Motley Fool • 07/04/26
Members of Congress Are Loading Up on Johnson & Johnson and UnitedHealth. Here's Why Retail Investors Should Pay Attention.The Motley Fool • 07/03/26
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?Zacks Investment Research • 07/02/26
Here's How Much You Need to Replace $70,000 in Salary With Dividend Income24/7 Wall Street • 07/02/26
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 07/01/26
Dow Jones Medical Giant J&J Breaks Out; PNC, Iron Mountain, Fortinet In Or Near Buy ZonesInvestors Business Daily • 06/30/26
J&J Wins CHMP Nod for Expanded Use of Multiple Myeloma Drug TecvayliZacks Investment Research • 06/29/26
Johnson & Johnson (JNJ) Surges 4.0%: Is This an Indication of Further Gains?Zacks Investment Research • 06/29/26